semaglutide manufacturers Health Canada approves generic Ozempic from Apotex as patients and insurers seek savings Wegovy-maker Novo Nordisk to spend

Patients with PCOS Polycystic ovary syndrome creates metabolic challenges that make weight management particularly difficult

Six patients were given 300 mg of IONIS-FXI Rx before and after hemodialysis in the first stage of the research

Retatrutide is a triple agonist covering GLP-1, GIP, and glucagon (GCGR) receptors in one molecule it already includes everything Ozempic does

Currently (February 2024), the EMA is considering the wider use of Wegovy to include reducing cardiovascular events this is critical for coverage in many European health systems, including the largest, Germany, which refuse to cover it for weight loss alone

Individual timelines vary, and healthcare provider guidance helps set realistic expectations based on specific goals and circumstances